Menu Search
Equities

Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd

688076:SHH

Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)53.74
  • Today's Change-0.04 / -0.07%
  • Shares traded2.93m
  • 1 Year change+60.75%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd grew revenues 58.69% from 651.29m to 1.03bn while net income improved 26.20% from 129.11m to 162.94m.
Gross margin64.95%
Net profit margin24.41%
Operating margin26.94%
Return on assets10.78%
Return on equity16.18%
Return on investment15.22%
More ▼

Cash flow in CNYView more

In 2023, Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd increased its cash reserves by 87.76%, or 316.69m. Cash Flow from Financing totalled 631.90m or 61.14% of revenues. In addition the company generated 350.21m in cash from operations while cash used for investing totalled 662.21m.
Cash flow per share--
Price/Cash flow per share--
Book value per share11.14
Tangible book value per share9.60
More ▼

Balance sheet in CNYView more

Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd has a Debt to Total Capital ratio of 33.52%, a higher figure than the previous year's 0.43%.
Current ratio1.37
Quick ratio1.03
Total debt/total equity0.5098
Total debt/total capital0.3352
More ▼

Growth rates in CNY

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 100.00% and 26.20%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
Div yield(5 year avg)0.35%
Div growth rate (5 year)--
Payout ratio (TTM)24.49%
EPS growth(5 years)22.72
EPS (TTM) vs
TTM 1 year ago		144.11
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.